Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment- a clinical appraisal
A clinical appraisal of existing scientific literature sought to assess the need for long-term prospective epidemiological studies to investigate an increased cancer risk of anti-hyperglycemic medication in type 2 diabetes. A focus statement was formulated as: “With a higher risk of cancers in patients with type 2 diabetes, all anti-hyperglycemic drugs should undergo long-term, prospective epidemiological studies for cancer risks.” Field surveys were sent to practicing physicians and endocrinologists to identify the currently prevalent level of accept ance of this statement.
Source: Journal of Diabetes and Its Complications - Category: Endocrinology Authors: Jiten Vora, Kausik Ray, Mikhail Kosiborod, Neil R. Poulter, Sanjay Rajagopalan, Lawrence A. Leiter Tags: Review article Source Type: research
More News: Cancer | Cancer & Oncology | Diabetes | Diabetes Type 2 | Endocrinology | Epidemiology | Legislation | Study